Objectives: Endovascular aneurysm repair for ruptured abdominal aortic aneurysms (r-EVAR) has increased over the years. Ruptured abdominal aortic aneurysms (rAAA) usually present with more hostile anatomy, and planning is performed under time pressure. Consequently, more complications during follow-up may arise. Additionally, it is unknown whether the same sac dynamics can be expected after repair between elective (el-EVAR) and r-EVAR. This study evaluated differences in outcomes and sac dynamics between r-EVAR and el-EVAR.
PC008.
Lower Extremity Ischemia and Limb Occlusion After Endovascular Aortic Aneurysm Repair in Global Registry for Endovascular Aortic Treatment (GREAT) Objectives: We evaluated the incidence of lower extremity ischemia and limb occlusion in patients undergoing endovascular aneurysm repair (EVAR) with the Excluder and C3 Excluder AAA Endoprosthesis (W. L. Gore and Associates Inc, Flagstaff, Ariz).
Methods:
The Global Registry for Endovascular Aortic Treatment (GREAT) is an industry-sponsored prospective, multicenter, cohort registry that enrolled >5000 consecutive patients to report real-world data for the Gore abdominal and thoracic aortic endografts. Patients who underwent EVAR for infrarenal abdominal aortic aneurysm from August 2010 to November 2016 were identified from the registry. The incidence and outcome of patients with lower extremity ischemia and endograft limb occlusion were analyzed. Statistical analysis was performed to identify factors associated with lower extremity ischemia.
Results: Among the 3649 patients who were treated with the Excluder and C3 Excluder devices in the registry, 44 patients (1.2%) developed lower extremity ischemia, 16 patients (36%) developed endograft limb occlusion, and 25 patients had common femoral, femoral popliteal, or distal thrombosis. The incidence of endograft-related limb ischemia was 0.4%. All patients required additional procedures for revascularization, and none require major extremity amputation. Patients who developed extremity ischemia were significantly younger, more likely to be female, had history of peripheral vascular disease (PVD), and had smaller distal limb diameter (Table) . In multivariable analysis, female gender (odds ratio [OR], 2.90; 95% confidence interval [CI], 1.52-5.52; P ¼ .001), younger age (OR, 0.96; 95% CI, 0.93-0.99; P ¼ .018), and history of PVD (OR, 5.96; 95% CI, 3.24-10.99; P < .001) were associated with lower extremity ischemia.
Conclusions: The incidences of lower extremity ischemia and endograft limb occlusion in real-world practice are uncommon with the Excluder endograft. Female gender, younger age, and history of PVD were factors associated with lower extremity ischemia after EVAR. The potential effects of annual surgeon composite volume and surgeon years of experience on postoperative outcomes were also explored.
Results: A total of 7211 elective open AAA repairs performed by 101 surgeons were included. Most of the operations were performed by vascular surgeons (81.5%), followed by cardiac (12.1%) and general surgeons (6.1%). Median number of procedures in the low quintile group was three repairs per year, while the very high quintile group performed 54 repairs per year. Overall 30-day mortality was 3%, with no effect of surgeon volume when comparing lowest volume to highest volume quintiles (P ¼ .21). The lowest volume group exhibited a higher 30-day complication rate (28.0% vs 20.4%; odds ratio, 1.54; 95% confidence interval, 1.15-2.06) and 30-day reoperation rate (10.53% vs 6.73%; odds ratio, 1.63; 95% confidence interval, 1.18-2.26) when compared to the highest volume group. No effect of surgeon volume on 1-year mortality, or 1-year reoperation was observed. Similarly, composite volume and surgeon years of experience did not significantly impact postoperative mortality.
Conclusions: Higher surgeon annual volume resulted in lower postoperative complication and reoperation rates, while having no effect on postoperative mortality. Surgeon years of experience did not influence outcomes suggesting that annual volume is more important than surgeon seniority in dictating outcomes after elective open AAA repair.
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PC012.

Contemporary Mortality Rates After Endovascular Aortic Repair in Patients Unfit for Open Aortic Surgery: Is It Time to Revisit Endovascular Aortic Repair-2 Trial?
Megan C. Turner, Shaunak Adkar, Harold J. Leraas, Uttara Nag, Brian F. Gilmore, Ryan S. Turley, Cynthia Shortell, Leila Mureebe. Duke University Medical Center, Durham, NC Objectives: The 2010 Endovascular Aortic Repair-2 Trial (EVAR-2) reported that patients with comorbidity profiles rendering them unfit for open aneurysm repair who underwent endovascular aortic repair (EVAR) did not result in a survival advantage compared those who did not undergo intervention. These patients experienced a 30-day mortality of 7.3%, while reports from similar cohorts report far lower mortality rates. The primary objective of our study was to compare the incidence of 30-day mortality in low-and high-risk patients undergoing EVAR in a contemporary dataset, using patient risk stratification criteria from EVAR-2. Secondarily, we sought to identify risk factors associated with a disproportionate contribution to 30-day mortality risk.
Methods: Data was obtained from the 2005 to 2013 American College of Surgeons National Surgical Quality Improvement Program participant user files (n ¼ 24,813). Patients were included in the high-risk cohort with the presence of renal, respiratory, or cardiac preoperative criteria alone or in combination. Renal criteria were defined as dialysis, or creatinine >2.26 mg/dL. Respiratory criteria included history of chronic obstructive pulmonary disease, or preoperative ventilator support. Cardiac criteria included history of myocardial infarction, congestive heart failure, angina, or prior coronary intervention. Patient, procedural characteristics and 30-day postoperative outcomes were compared using Pearson c 2 tests for categoric variables and Wilcoxon rank sum tests for continuous variables.
Results: Among 24,813 patients undergoing EVAR, 12,031 patients (48%) were characterized as high-risk while 12,770 patients (52%) were stratified as low-risk. Thirty-day mortality rate in the high-risk cohort was 1.9%, compared to the 7.3% reported by EVAR-2, and higher in the high-risk cohort compared to the low-risk cohort (1.9% vs 0.9%; P < .001). While the presence of each comorbidity increased the odds of 30-day mortality (respiratory: odds ratio [OR], 1.62; 95% confidence interval [CI], 1.16-2.26; P ¼ .005; cardiac: OR, 1.55; 95% CI, 1.14-2.10; P ¼ .005), the presence of renal criteria disproportionately increased the odds of mortality threefold (OR, 3.42; 95% CI: 2.31-5.09; P < .001). Thirty-day mortality rates compounded with increasing numbers of comorbidities: patients with one comorbidity criterion experienced a 1.6% 30-day mortality, up to 8.7% in patients meeting three criteria (P < .001).
Conclusions: Contemporary 30-day mortality following EVAR in highrisk patients is substantially lower than that reported in the EVAR-2 trial. While low-and high-risk stratification by current comorbidity criteria is appropriate, attention needs to be paid to disproportionate risk contribution from renal disease on mortality compared to cardiac and pulmonary comorbidities. Given the lower mortality risk than previously described, patients stratified as high-risk should be thoughtfully considered for definitive endovascular aneurysm repair.
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PC014.
Challenging Iliac Anatomy in Fenestrated Endovascular Aortic Aneurysm Repair Objectives: Fenestrated/branched endovascular repair (F/BEVAR) is a complex procedure that can be complicated, prolonged, and/or aborted due to difficult access vessel issues. Specifically, patients with significant aortoiliac occlusive disease, pre-existing endografts, and/or unilateral iliac occlusion represent a unique cohort with limited data regarding outcomes after F/BEVAR. This study describes our experience with challenging iliac anatomy in F/BEVAR patients.
Methods: A retrospective analysis of a prospectively maintained F/BEVAR database was performed on all procedures from 2009 to 2016. Operative details, including access vessel delivery approach, adjunct procedures, open/endovascular conduit use, and device configuration was abstracted. Challenging iliac anatomy was defined by use of open/ endoconduit, preemptive iliac angioplasty, aortouniiliac devices, and/or 30-day mortality 2 (3.6) 9 (3.4) .97
Postoperative complication 11 (19) 38 (14) .34
a Data are presented as number (%) or mean 6 standard deviation.
